On November 3, 2025, Mind Med, a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced it closed approximately a $249-million underwritten public offering which includes a full exercise of the underwriter’s option to purchase additional shares.

Osler, Hoskin & Harcourt LLP acted as Canadian counsel to MindMed with a team consisting of Trevor Scott, Minji Park and Julia McCarty (Corporate) and Kim Maguire (Tax).